Literature DB >> 25572503

Cost-effectiveness of revascularization strategies: the ASCERT study.

Zugui Zhang1, Paul Kolm2, Maria V Grau-Sepulveda3, Angelo Ponirakis4, Sean M O'Brien3, Lloyd W Klein5, Richard E Shaw6, Charles McKay7, David M Shahian8, Frederick L Grover9, John E Mayer10, Kirk N Garratt11, Mark Hlatky12, Fred H Edwards13, William S Weintraub2.   

Abstract

BACKGROUND: ASCERT (American College of Cardiology Foundation and the Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies) was a large observational study designed to compare the long-term effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) to treat coronary artery disease (CAD) over 4 to 5 years.
OBJECTIVES: This study examined the cost-effectiveness of CABG versus PCI for stable ischemic heart disease.
METHODS: The Society of Thoracic Surgeons and American College of Cardiology Foundation databases were linked to the Centers for Medicare and Medicaid Services claims data. Costs for the index and observation period (2004 to 2008) hospitalizations were assessed by diagnosis-related group Medicare reimbursement rates; costs beyond the observation period were estimated from average Medicare participant per capita expenditure. Effectiveness was measured via mortality and life-expectancy data. Cost and effectiveness comparisons were adjusted using propensity score matching with the incremental cost-effectiveness ratio expressed as cost per quality-adjusted life-year gained.
RESULTS: CABG patients (n = 86,244) and PCI patients (n = 103,549) were at least 65 years old with 2- or 3-vessel coronary artery disease. Adjusted costs were higher for CABG for the index hospitalization, study period, and lifetime by $10,670, $8,145, and $11,575, respectively. Patients undergoing CABG gained an adjusted average of 0.2525 and 0.3801 life-years relative to PCI over the observation period and lifetime, respectively. The life-time incremental cost-effectiveness ratio of CABG compared to PCI was $30,454/QALY gained.
CONCLUSIONS: Over a period of 4 years or longer, patients undergoing CABG had better outcomes but at higher costs than those undergoing PCI.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery bypass graft; incremental cost-effectiveness ratio; percutaneous coronary intervention; stable ischemic heart disease

Mesh:

Year:  2015        PMID: 25572503      PMCID: PMC5697906          DOI: 10.1016/j.jacc.2014.09.078

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  The STS National Database: current changes and challenges for the new millennium. Committee to Establish a National Database in Cardiothoracic Surgery, The Society of Thoracic Surgeons.

Authors:  T B Ferguson; S W Dziuban; F H Edwards; M C Eiken; A L Shroyer; P C Pairolero; R P Anderson; F L Grover
Journal:  Ann Thorac Surg       Date:  2000-03       Impact factor: 4.330

2.  The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository.

Authors:  R G Brindis; S Fitzgerald; H V Anderson; R E Shaw; W S Weintraub; J F Williams
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

3.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

Authors:  Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting
Journal:  J Am Coll Cardiol       Date:  2011-11-07       Impact factor: 24.094

4.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

5.  Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.

Authors:  William S Weintraub; Zefeng Zhang; Elizabeth M Mahoney; Paul Kolm; John A Spertus; Jaime Caro; Jack Ishak; Robert Goldberg; Joseph Tooley; Richard Willke; Bertram Pitt
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

6.  Selection of surgical or percutaneous coronary intervention provides differential longevity benefit.

Authors:  Peter K Smith; Robert M Califf; Robert H Tuttle; Linda K Shaw; Kerry L Lee; Elizabeth R Delong; R Eric Lilly; Michael H Sketch; Eric D Peterson; Robert H Jones
Journal:  Ann Thorac Surg       Date:  2006-10       Impact factor: 4.330

7.  A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort.

Authors:  A Peeters; A A Mamun; F Willekens; L Bonneux
Journal:  Eur Heart J       Date:  2002-03       Impact factor: 29.983

8.  ASCERT: the American College of Cardiology Foundation--the Society of Thoracic Surgeons Collaboration on the comparative effectiveness of revascularization strategies.

Authors:  Lloyd W Klein; Fred H Edwards; Elizabeth R DeLong; Laura Ritzenthaler; George D Dangas; William S Weintraub
Journal:  JACC Cardiovasc Interv       Date:  2010-01       Impact factor: 11.195

9.  Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease.

Authors:  Edward L Hannan; Chuntao Wu; Gary Walford; Alfred T Culliford; Jeffrey P Gold; Craig R Smith; Robert S D Higgins; Russell E Carlson; Robert H Jones
Journal:  N Engl J Med       Date:  2008-01-24       Impact factor: 91.245

10.  Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients.

Authors:  William S Weintraub; William E Boden; Zugui Zhang; Paul Kolm; Zefeng Zhang; John A Spertus; Pamela Hartigan; Emir Veledar; Claudine Jurkovitz; Jim Bowen; David J Maron; Robert O'Rourke; Marcin Dada; Koon K Teo; Ron Goeree; Paul G Barnett
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2008-09
View more
  14 in total

1.  Cognitive Change After Cardiac Surgery Versus Cardiac Catheterization: A Population-Based Study.

Authors:  Elizabeth L Whitlock; L Grisell Diaz-Ramirez; Alexander K Smith; W John Boscardin; Michael S Avidan; M Maria Glymour
Journal:  Ann Thorac Surg       Date:  2018-12-18       Impact factor: 4.330

2.  Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG?

Authors:  Pranav Kansara; Sandra Weiss; William S Weintraub; Matthew C Hann; James Tcheng; S Tanveer Rab; Lloyd W Klein
Journal:  JACC Cardiovasc Interv       Date:  2015-11       Impact factor: 11.195

3.  Treatment selection and medication adherence for stable angina: The role of area-based health literacy.

Authors:  Samuel T Savitz; Stacy Cooper Bailey; Stacie B Dusetzina; W Schuyler Jones; Justin G Trogdon; Sally C Stearns
Journal:  J Eval Clin Pract       Date:  2020-01-28       Impact factor: 2.431

4.  Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort Data.

Authors:  Brandon K Bellows; Yiyi Zhang; Zugui Zhang; Donald M Lloyd-Jones; Adam P Bress; Jordan B King; Paul Kolm; William C Cushman; Karen C Johnson; Leonardo Tamariz; Elizabeth C Oelsner; Steven Shea; Anne B Newman; Diane G Ives; David Couper; Andrew E Moran; William S Weintraub
Journal:  J Am Heart Assoc       Date:  2021-05-06       Impact factor: 5.501

5.  Stable ischemic heart disease in the older adults.

Authors:  Xuming Dai; Jan Busby-Whitehead; Daniel E Forman; Karen P Alexander
Journal:  J Geriatr Cardiol       Date:  2016-02       Impact factor: 3.327

Review 6.  Advances in Cardiovascular Care: How to Stimulate Innovation While Controlling Cost.

Authors:  William S Weintraub; Kelvin H Lee
Journal:  JACC Basic Transl Sci       Date:  2018-03-01

Review 7.  Role of Big Data in Cardiovascular Research.

Authors:  William S Weintraub
Journal:  J Am Heart Assoc       Date:  2019-07-11       Impact factor: 5.501

Review 8.  Cost-effectiveness analysis in cardiac surgery: A review of its concepts and methodologies.

Authors:  Bart S Ferket; Jonathan M Oxman; Alexander Iribarne; Annetine C Gelijns; Alan J Moskowitz
Journal:  J Thorac Cardiovasc Surg       Date:  2017-11-15       Impact factor: 5.209

9.  Machine-Learning Techniques for Feature Selection and Prediction of Mortality in Elderly CABG Patients.

Authors:  Yen-Chun Huang; Shao-Jung Li; Mingchih Chen; Tian-Shyug Lee; Yu-Ning Chien
Journal:  Healthcare (Basel)       Date:  2021-05-07

10.  Health utility indexes in patients with acute coronary syndromes.

Authors:  Baris Gencer; Nicolas Rodondi; Reto Auer; David Nanchen; Lorenz Räber; Roland Klingenberg; Mark Pletscher; Peter Jüni; Stephan Windecker; Christian M Matter; Thomas F Lüscher; François Mach; Thomas V Perneger; François R Girardin
Journal:  Open Heart       Date:  2016-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.